Dr. Johnson on the Results of the CITYSCAPE Trial in PD-L1+ NSCLC

May 28th, 2020 - Melissa L. Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the results of the phase 2 CITYSCAPE trial in PD-L1–positive non–small cell lung cancer (NSCLC).

Dr. You on Findings from the TROPHIMMUN Study in Gestational Trophoblastic Tumors

May 28th, 2020 - Benoit You, MD, PhD, academic staff physician in the Medical Oncology Department of Lyon University Hospital, discusses the findings of the phase 2 TROPHIMMUN study which treated chemotherapy-resistant gestational trophoblastic tumors with avelumab (Bavencio).

Dr. Powles on Maintenance Avelumab in Urothelial Carcinoma

May 28th, 2020 - Thomas Powles, MD, MBBS, MRCP, director, Barts Cancer Institute, discusses the utility of maintenance avelumab (Bavencio) in the phase 3 JAVELIN Bladder 100 study in advanced urothelial carcinoma.

OncLive News Network On Location: ASCO 2020 Day 2

May 30th, 2020 - We are recapping some of the top news that have been presented during the conference—and soon we’ll speak with Drs Brian Rini and Christopher Sweeney on some significant data being presented in genitourinary cancers, as well as Dr Roy Herbst on some practice-changing lung cancer studies.

Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors

May 29th, 2020 - Brian A. Van Tine, MD, PhD, associate professor in the Department of Medicine, director, Sarcoma Program, Division of Medical Oncology, Washington University School of Medicine in St. Louis, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.

Dr. Choueiri on Results of the SAVOIR Trial in MET-Driven Papillary RCC

May 28th, 2020 - Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses results of the phase 3 SAVOIR trial evaluating the MET inhibitor savolitinib versus sunitinib (Sutent) in patients with MET-driven papillary renal c...

Dr. Lin on Updated Findings of HER2CLIMB Study in HER2+ Breast Cancer Brain Mets

May 28th, 2020 - Nancy U. Lin, MD, associate professor of medicine at Harvard Medical School; associate chief of the Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers; director of the Metastatic Breast Cancer Program and senior physician at Dana-Farber Cancer Institute, discusses updated findings from the phase 2 HER2CLIMB study in patients with HER2-positive metastatic breast cancer with b...

Dr. Munshi on the Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

May 28th, 2020 - Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Kraft Family Chair, senior physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Lonial on the Results of the DREAMM-2 Trial in Multiple Myeloma

May 28th, 2020 - Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the results of the phase 2 DREAMM-2 trial in multiple myeloma.

OncLive News Network On Location: ASCO 2020 Day 1

May 29th, 2020 - We are recapping some of the top news that have been presented during the conference—and soon we’ll speak with Dr Melissa Johnson on some of the practice-changing lung cancer data being presented, Dr Milind Javle on some pivotal gastrointestinal cancer abstracts, and Dr Hope Rugo on the biggest studies in breast cancer.

Dr. Berdeja on Updated CARTITUDE-1 Results in Multiple Myeloma

May 28th, 2020 - Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses updated results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) in multiple myeloma.

Dr. Kuruvilla on Findings From the KEYNOTE-204 Trial in Hodgkin Lymphoma

May 28th, 2020 - John Kuruvilla, MD, FRCPC, clinician investigator, Cancer Clinical Research Unit, Princess Margaret Cancer Centre, discusses findings from the phase 3 KEYNOTE-204 trial in Hodgkin lymphoma.